English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

On April 22, 2015, Science Translational Medicine published two papers under one theme: testing cancer drugs in vivo and in situ. Both papers reported on patient-friendly devices that can predict patients’ sensitivity or susceptibility to chemotherapeutic agents, before surgery and the start of a systemic therapy regimen. The devices could change how clinicians treat cancers, improving efficacy and decreasing cost while creating opportunities to improve current drug discovery, testing, and trial practices.  One unnamed device designed by Oliver Jonas, Ph.D., and colleagues from the group of Robert Langer, Ph.D., at the Massachusetts Institute of Technology in Cambridge, Mass., is an implantable microdevice that leaks out microdoses of drugs to test both efficacy and patient sensitivity (Sci. Trans. Med. 2015;7:284ra57). “You can use it to test a patient for a range of available drugs and pick the one that works best,” Jonas said.  A second device is a hand-held injectable CIVO developed by Richard Klinghoffer, Ph.D., and colleagues at Presage Biosciences in collaboration with James Olson, Ph.D., and colleagues at Fred Hutchinson Cancer Research Center, all in Seattle. The CIVO device, the size of a pen flashlight, also delivers microdoses of drugs into various tumor sites for testing (Sci. Trans. Med. 2015;7:284ra58). “[Our] approach enables drug developers to analyze and compare multiple drugs and drug combinations in a single living tumor while [they are] still in the patient,” Klinghoffer said.

Personalized Devices Predict Cancer Drug Sensitivity In Vivo: